Engineered Gene Mutation Could Shield Against Most Viruses: Study
(MENAFN) A groundbreaking study published in Science Translational Medicine reveals that replicating a rare genetic mutation could pave the way for near-universal protection against viruses, a science news website reported Tuesday.
Researchers have successfully recreated a deficiency in interferon-stimulated gene 15 (ISG15)—a mutation linked to exceptional virus resistance—in laboratory animals. This discovery raises the possibility of developing new therapies that harness this natural defense.
Individuals with ISG15 deficiency endure mild, chronic inflammation but maintain constantly active antiviral proteins. Despite exposure to common viruses such as influenza, measles, and chickenpox, they experience only mild symptoms.
"In the back of my mind, I kept thinking that if we could produce this type of light immune activation in other people, we could protect them from just about any virus," said Columbia University immunologist Dusan Bogunovic, who identified the mutation 13 years ago.
Using mRNA vaccine technology, Bogunovic and his team induced a temporary ISG15 deficiency in mice and hamsters. The treated animals produced 10 crucial antiviral proteins that disrupted viral infection at multiple stages.
When exposed to SARS-CoV-2, these proteins limited infection without compromising the animals' broader immune responses.
"We only generate a small amount of these 10 proteins, for a very short time, and that leads to much less inflammation than what we see in ISG15-deficient individuals," Bogunovic explained, emphasizing that the inflammation is "enough" to prevent viral diseases.
Although protection lasted up to four days, this method could offer vital short-term immunity for healthcare workers until specific vaccines are developed.
While still in early stages, this approach holds potential to bolster defenses against future pandemics such as COVID-19 or the Spanish Flu. However, significant challenges remain in safely delivering mRNA therapies to targeted sites in humans.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
